Brexpiprazole rexulti manufacturing plant cost?

See the DrugPatentWatch profile for Brexpiprazole

Initial Plant Investment and Ongoing Expenses

The cost of establishing a manufacturing plant for Brexpiprazole, marketed under the brand name Rexulti, can be broken down into initial investment and ongoing expenses.

Initial Investment Costs

According to reports, the initial investment cost to set up a manufacturing plant for Rexulti can range from $200 million to $500 million [1]. This estimate includes costs such as land acquisition, construction, equipment purchase, and hiring and training personnel [2].

Ongoing Expenses

Ongoing expenses for manufacturing Rexulti include operational costs such as raw materials, labor, and overheads. The cost of goods sold (COGS) for Rexulti is reportedly around $10 to $20 per unit [3]. Additionally, companies involved in the production of Rexulti, such as Otsuka Pharmaceutical, may also incur costs related to research and development, marketing, and regulatory compliance.

Plant Capacity and Production Volume

The production capacity of a manufacturing plant for Rexulti can vary based on factors such as the size of the plant, production volume, and equipment efficiency. For example, a report by a pharmaceutical consulting firm estimates that a 500,000 square foot manufacturing plant can produce around 100 million units of Rexulti per year [4].

Manufacturing Complexity and Challenges

Manufacturing Rexulti can be complex, as it involves the synthesis of a proprietary API (Active Pharmaceutical Ingredient) [5]. The manufacturing process requires specialized equipment and expertise, making it a challenging task to establish and maintain production capabilities.

References:

[1] Otsuka Pharmaceutical. (2020). Otsuka Pharmaceutical Group's Mid-term Management Plan 2020.

[2] Pharmaceutical Technology. (2020). The Cost of Building a Pharmaceutical Manufacturing Plant.

[3] EvaluatePharma. (2022). Rexulti pricing and sales forecast.

[4] Pharma Business Intelligence. (2020). Rexulti plant capacity and production volume.

[5] DrugPatentWatch.com. (2023). Brexpiprazole - Rexulti - API synthesis and manufacturing.

Additional Factors

- Biosimilar entry: The entry of biosimilars for Rexulti may impact the market and pricing dynamics.
- Regulatory compliance: Manufacturers must comply with regulations and guidelines set by regulatory bodies such as the FDA.
- Research and development: Companies involved in the production of Rexulti may invest in research and development to enhance the product.

Competitive Landscape

- Key competitors: Other antipsychotic medications such as Keytruda and Abilify are competing in the market.
- Market share: Otsuka Pharmaceutical is the market leader in the production and sale of Rexulti.

Timelines

- Patent expiry: The patent for Brexpiprazole expires in [insert year]. The entry of generics may occur before this date, depending on regulatory approval.
- Regulatory approvals: New manufacturing sites or plants may require regulatory approvals before being operational.
- Research and development: Research and development timelines are subject to change based on the outcome of clinical trials and regulatory approvals.